Literature DB >> 28965334

A case of choroidal neovascular membrane in 6-year-old boy with juvenile idiopathic arthritis.

Parthopratim Dutta Majumder1, Avirupa Ghose2, Chetan Rao3, Muna Bhende3, Jyotirmay Biswas4.   

Abstract

PURPOSE: The purpose of this study is to report a case of choroidal neovascular membrane (CNVM) in a patient of juvenile idiopathic arthritis (JIA).
DESIGN: The design of this study is an interventional case report.
METHODS: A 6-year-old boy, a known patient of JIA, presented with a complaint of redness and ocular pain with mild diminution of vision in his left eye. Fundus examination revealed a CNVM with retinal thickening and subretinal fluid which was confirmed on OCT. Treatment with intravitreal injection of anti-VEGF (ranibizumab) and oral immunosuppressive showed resolution of the CNVM.
RESULTS: The result of this study is a successful treatment of CNVM with a single anti-VEGF injection and systemic immunosuppression.
CONCLUSIONS: Although a rare complication, CNVM can occur in patients with JIA.

Entities:  

Year:  2017        PMID: 28965334      PMCID: PMC5622887          DOI: 10.1186/s12348-017-0136-1

Source DB:  PubMed          Journal:  J Ophthalmic Inflamm Infect        ISSN: 1869-5760


Introduction

Choroidal neovascular membrane (CNVM) is a vision-robbing complication of uveitis. It is characterized by pathologic blood vessel growth from the choroid across Bruch’s membrane into the retina and often resulting in central vision loss. The incidence of CNVM due to uveitis has been reported to 2% and usually affects young individuals [1]. The prevalence of CNVM secondary to uveitis varies among different uveitic entities but is most commonly reported in patients with posterior uveitis and panuveitis [1-3]. CNVM in intermediate uveitis is relatively uncommon but has been reported in literature [4-6]. CNVM can occur as a result of any pathologic process that involves RPE and Bruch’s membrane [7]. Juvenile idiopathic arthritis (JIA) is the most common extraocular disease associated with uveitis in children. JIA-associated uveitis has plethora of clinical presentations and considered as a significant cause of ocular morbidity in children. Various complications have been reported to be associated with JIA: band keratopathy, cataract, glaucoma, ocular hypotony, and vision-robbing maculopathies like macular edema and epiretinal membrane. To the best of our knowledge, CNVM secondary to JIA has not been yet reported in literature. We, in hitherto, report a case of CNVM in a patient of JIA.

Case report

A 6-year-old emmetropic boy, a known patient of JIA, presented to our outpatient department with a complaint of redness and ocular pain with mild diminution of vision in his left eye. He was started on oral methotrexate on account of recurrent attacks of anterior uveitis 3 months back, and at the time of presentation, he was on oral methotrexate 7.5 mg/week. He was extensively investigated to rule out other possible causes of intraocular inflammation including infectious etiology. His best-corrected visual acuity (BCVA) on presentation was 6/7.5 in the left eye. Ocular examination revealed a decrease in best-corrected visual acuity of 6/9 in the left eye. Slit-lamp examination of the right eye showed quiet anterior chamber and few cells in anterior vitreous. Fundus examination of the right eye was normal. Slit-lamp examination of the left eye showed early band-shaped keratopathy, occasional cells (0.5+) in anterior chamber and cells in anterior vitreous. Fundus examination of the left eye showed a yellowish lesion with overlying subretinal fluid just inferior to fovea (Fig. 1a). Fundus fluorescein angiography of the left eye showed no obvious leakage in the early phase, faint hyperfluorescence in the mid phase, and intense hyperfluorescence with leakage in the late phase (Fig. 2a–c). Optical coherence tomography of the left eye showed a CNVM with retinal thickening and subretinal fluid (Fig. 1b). A diagnosis of inflammatory CNVM was made. Dose of oral methotrexate was hiked up to 10 mg/week, and intravitreal injection of anti-VEGF (ranibizumab) was administered in the left eye. Patient was examined again after a month. His BCVA improved to 6/6, and slit-lamp examination of his left eye showed a quiet AC and few old, pigmented cells in anterior vitreous. Fundus examination of the left eye showed healed CNVM and resolution of subretinal fluid, which was confirmed by optical coherence tomography (Fig. 3a, b). Patient was maintained on methotrexate 10 mg weekly. Patient is under a regular follow-up with us for last 9 months. There has been no recurrence in uveitis or CNVM till date.
Fig. 1

a Color fundus photograph of the left eye on presentation. b Optical coherence tomography through the lesion showing the choroidal neovascular membrane, retinal thickening, and subretinal fluid

Fig. 2

Fundus fluorescein angiography of the left eye showing a no obvious leakage in the early phase, b faint hyperfluorescence in the mid phase, and c intense hyperfluorescence with leakage in the late phase

Fig. 3

a Color fundus photograph of the left eye at 1-month follow-up. b Optical coherence tomography showing the scarred choroidal neovascular membrane and resolution of subretinal fluid

a Color fundus photograph of the left eye on presentation. b Optical coherence tomography through the lesion showing the choroidal neovascular membrane, retinal thickening, and subretinal fluid Fundus fluorescein angiography of the left eye showing a no obvious leakage in the early phase, b faint hyperfluorescence in the mid phase, and c intense hyperfluorescence with leakage in the late phase a Color fundus photograph of the left eye at 1-month follow-up. b Optical coherence tomography showing the scarred choroidal neovascular membrane and resolution of subretinal fluid

Discussion

Literature on posterior segment involvement in JIA is relatively rare [8-11]. Macular involvement in JIA might be much more common than has been reported in literature. In a retrospective review of 67 patients with JIA, 37.1% had posterior complications, 13.8% had macular edema, 12% papillitis, 6.8% epiretinal membrane, 2.5% retinal vasculitis, and 1.7% retinal detachment [11]. In a cross-sectional prospective study in 62 eyes of 38 patients with JIA-associated uveitis, maculopathy was noted in 82% of the eyes [9]. This study highlights the importance of optical coherence tomography, which can detect subtle macular changes that are not identifiable on biomicroscopy. Our findings of CNVM in a child with JIA may be explained with the concept that CNVM is driven at least in part by the intraocular inflammation. CNVM is relatively uncommon among patients with anterior and intermediate uveitis but not rare [6, 12]. Breakdown of blood-retinal barrier and the role of several inflammatory and vasoactive peptides have been implicated as the cause of macular edema in JIA [13]. Our case clearly demonstrated OCT and angiographic evidence of CNVM in a patient of JIA in the absence of other identifiable causes. Based on our finding, we conclude that CNVM is a rare complication of JIA and usually have a favorable outcome if diagnosed early and treated with anti-VEGF and systemic immunosuppression.

Conclusion

To the best of our knowledge, this is the first reporting of CNVM in a patient with JIA. Though occurrence of CNMV can be multifactorial, the absence of other factors like myopia and history of trauma in a child with on-going intraocular inflammation helped us arrive at this conclusion.
  13 in total

1.  Retinal complications of juvenile idiopathic arthritis-related uveitis: a microperimetry and optical coherence tomography study.

Authors:  Maria Pia Paroli; Giovanni Spinucci; Claudia Fabiani; Paola Pivetti-Pezzi
Journal:  Ocul Immunol Inflamm       Date:  2010-01       Impact factor: 3.070

2.  Risk of choroidal neovascularization among the uveitides.

Authors:  Sally L Baxter; Maxwell Pistilli; Siddharth S Pujari; Teresa L Liesegang; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; John H Kempen
Journal:  Am J Ophthalmol       Date:  2013-06-21       Impact factor: 5.258

3.  Juvenile arthritis-associated uveitis: visual outcomes and prognosis.

Authors:  Celia S Chen; Don Roberton; Michael E Hammerton
Journal:  Can J Ophthalmol       Date:  2004-10       Impact factor: 1.882

4.  Prognosis of juvenile rheumatoid arthritis-associated uveitis.

Authors:  M P Paroli; S Speranza; M Marino; M P Pirraglia; P Pivetti-Pezzi
Journal:  Eur J Ophthalmol       Date:  2003 Aug-Sep       Impact factor: 2.597

Review 5.  Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.

Authors:  Claudio Campa; Ciro Costagliola; Carlo Incorvaia; Carl Sheridan; Francesco Semeraro; Katia De Nadai; Adolfo Sebastiani; Francesco Parmeggiani
Journal:  Mediators Inflamm       Date:  2010-08-25       Impact factor: 4.711

6.  Peripapillary subretinal neovascularization in peripheral uveitis.

Authors:  D F Arkfeld; R J Brockhurst
Journal:  Retina       Date:  1985 Summer-Fall       Impact factor: 4.256

7.  Intermediate uveitis complicated by choroidal granuloma following subretinal neovascular membrane: case reports.

Authors:  Carlos Alexandre de Amorim Garcia; Paulo de Souza Segundo; Carlos Alexandre de Amorim Garcia Filho; Ana Cláudia Medeiros de Amorim Garcia
Journal:  Arq Bras Oftalmol       Date:  2008 Nov-Dec       Impact factor: 0.872

8.  Severe macular edema in patients with juvenile idiopathic arthritis-related uveitis.

Authors:  Maria Pia Paroli; Claudia Fabiani; Giovanni Spinucci; Irene Abicca; Alfredo Sapia; Leopoldo Spadea
Journal:  Case Rep Ophthalmol Med       Date:  2013-08-19

9.  Peripapillary choroidal neovascularization in pars planitis.

Authors:  Sonia Mehta; Luxme Hariharan; Allen C Ho; John H Kempen
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-01-15

10.  Choroidal neovascularization secondary to tubulointerstitial nephritis and uveitis syndrome (TINU) in an adult patient.

Authors:  Hans Barron Heymann; Daniel Colon; Manjot K Gill
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.